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ABSTRACT 
Objective: To develop and validate a simple, specific, accurate, precise and sensitive reverse phase high performance liquid chromatographic (RP-HPLC) 
method with forced degradation studies for the simultaneous estimation of amlodipine besylate and irbesartan in the pharmaceutical formulation.  
Methods: The chromatographic separation of the two drugs were achieved using Enable C 18G column (250 ×4.6 mm; 5 µm) in isocratic mode with mobile 
phase consisting of sodium acetate buffer (pH 4.0) and acetonitrile (30:70, % v/v) with a flow rate of 0.6 ml/min. Ultraviolet(UV) detection was carried out at 
238 nm. The proposed method was validated for linearity, range, accuracy, precision, robustness, limit of detection (LOD) and limit of quantification (LOQ). 
The tablet formulation was subjected to stress conditions of degradation including acidic, alkaline, oxidative, thermal and photolysis. 
Results: The retention time for amlodipine besylate and irbesartan were found to be 5.512 and 6.321 min respectively. Linearity was observed over 
a concentration range 4-32 µg/ml for amlodipine besylate (r2 =0.9999) and 10-70 µg/ml for Irbesartan (r2
Conclusion: The developed reverse phase high performance liquid chromatographic (RP-HPLC) method was also found to be simple, precise and 
sensitive for the simultaneous determination of amlodipine besylate and irbesartan in the tablet dosage form. 
 =0.9998). The % relative standard 
deviation (RSD) for Intraday and Interday precision was found to be 0.436 and 0.699 for amlodipine besylate and 0.435 and 0.30 for irbesartan. 
Amlodipine besylate shown stability towards acidic and thermal whereas in basic, oxidative and photolytic it shown less stability in which it 
degraded to more extent. Irbesartan shown stability towards thermal conditions whereas in remaining conditions it degrades to more extent 
especially in oxidative conditions. 
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Amlodipine besylate (fig. 1), chemically designated as 2-[(2-
aminoethoxy)-methyl]-4-(2-chlorophenyl) 1,4-dihydro-6-methyl-3,5-
pyridine-dicarboxylic acid-3 ethyl-5 methyl ester, is a calcium channel 
blocker used to treat hypertension and angina. The drug is found to 
metabolize in the liver and the produced metabolites are excreted via 
urine along with some unchanged drug. Literature survey reveal 
various analytical method are reported either alone or combination 
with other drugs includes UV spectrophotometric[1-4], Visible 
spectrophotometric [5-7], spectrofluorometric [8], Titrimetry [5], LC-
MS [9], HPLC [10, 11] in pure drug, pharmaceutical formulations and 
biological fluids.  
Irbesartan (fig. 2) is an angiotensin II receptor antagonist used in the 
management of hypertension including treatment of renal disease in 
hypertensive type II diabetic patients. It possesses an acidic 
tetrazole system and biphenyl system, does not have acidic side 
chain and even so it has good affinity for angiotensin II receptor 
because of hydrogen bonding with the carbonyl moiety of amide 
system. It decreases afterload and preload. It is more effective in 
providing 24 hr control of blood pressure. Combination therapy of 
hypertension with different categories offers the potential to lower 
blood pressure more quickly, obtain target blood pressure, and 
decrease adverse effects. The combination tablet containing 
amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering 
effect than an angiotensin receptor blocker (ARB) and a low-dose or 
regular-dose calcium channel blocker (CCB). In addition, the 
combination tablet had more favorable effects on serum uric acid, 
low-density lipoprotein cholesterol, and high-density lipoprotein 
cholesterol levels in patients with hypertension [12]. Several 
analytical methods have been reported for the determination of 
Irbesartan either alone or in combination with other drugs in pure 
drug, pharmaceutical dosage forms and in biological samples using 
spectrophotometry [13-16], HPLC [17-39], HPTLC [40-42], LC-MS 
[43-45], and voltammetry [46] for the determination of irbesartan in 
pharmaceutical dosage forms. The combination of amlodipine 
besylate and irbesartan is effective in the treatment of hypertention. 
Various analytical methods were reported for simultaneous 
estimation of amlodipine besylate and irbesartan in pure drug, 
pharmaceutical formulations and biological fluids by HPLC [47-49]. 
Only one stability indicating RP-HPLC method was reported for the 
simultaneous estimation of both drugs in pharmaceutical 
formulation but the developed method has long retention time and 
low linearity range for both drugs. Therefore in the present study, an 
attempt was made to develop a simple, precise, accurate RP-HPLC 
method with forced degradation studies for the analysis of 
amlodipine besylate and irbesartan in pharmaceutical formulation. 
 
 
Fig. 1: Structure of amlodipine besylate 
 
 
Fig. 2: Structure of Irbesartan 
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MATERIALS AND METHODS 
Materials and chemicals 
Amlodipine Besylate and Irbesartan standard were obtained as 
gifted sample from pharma industry. Amlodipine Besylate and 
Irbesartan Tablets (AMIX R TABLETS) containing Irbesartan 100 mg 
and amlodipine 10 mg were purchased from a local pharmacy. HPLC 
grade Acetonitrile and water were from MERCK India Ltd. HPLC 
grade methanol was from standard reagent pvt ltd Hyderabad. 
Analytical grade acetic acid, sodium acetate, hydrochloric acid, 
sodium hydroxide and hydrogen peroxide were from SD Fine 
chemicals Mumbai, India. Nylon membrane filters 0.2 µm and 0.45 
µm were from PALL life sciences Mumbai India. Ultrasonicator used 
was from LAB india Ltd Mumbai. pH
Instrumentation 
 meter was of Elico LI 120 make. 
UV spectrophotometer was of Elico SL 210 model consisted of 
spectral treats software. 
The chromatographic system used for the method development and 
validation consisted of Shimadzu HPLC comprising of LC-20AD 
binary gradient pump, a variable wavelength programmable SPD-
20A detector and an SCL 20A system controller. A Rheodyne injector 
7725i fitted with a 20 μL loop was used and data were recorded and 
evaluated by use of LC solutions software version 5.0.  
Chromatographic conditions 
Chromatographic analysis was performed on Enable C18 G column 
(250 x 4.6 mm i. d, 5µ). The mobile phase consisted of sodium 
acetate buffer (pH 4.0) and acetonitrile (30:70, %v/v). The flow rate 
was 0.6 ml/min, injection volume was 20 µl and detection was 
carried out at 238 nm using a UV detector. 
Preparations of amlodipine besylate and irbesartan stock solution 
Stock solution of amlodipine besylate (1000 µg/ml) and 
irbesartan(1000 µg/ml) was prepared separately by transferring 
accurately weighed 50 mg of amlodipine besylate and 50 mg of 
Irbesartan into a 50 ml volumetric flask and to it added a 20 ml 
methanol. The mixture was sonicated for 5 min to dissolve the drug 
and the solution was diluted up to the mark with methanol. Standard 
solution amlodipine besylate (100 µg/ml) and irbesartan (100 µg/ml) 
were prepared by diluting 10 ml of standard stock solution to 100 ml 
in a volumetric flask with mobile phase. To prepare a binary mixture 
of irbesartan and amlodipine besylate appropriate volume of standard 
solution was transferred into a 100 ml volumetric flask and diluted 
with mobile phase to get a solution containing 100 µg/ml of irbesartan 
and 10 µg/ml of amlodipine besylate. 
Analysis of amlodipine besylate and irbesartan in combined 
dosage form 
Accurately weighed about twenty tablets and average weight of the 
tablet was determined. The tablets were transferred into mortar and 
triturated to a fine powder form. An a liquate of the powder 
equivalent to 100 mg of irbesartan and 10 mg of amlodipine besylate 
was transferred into a 100 ml volumetric flask. To it 20 ml HPLC 
grade methanol was added and sonicated for 5 min to dissolve the 
drugs. The content of the flask was kept for 10 min at laboratory 
temperature and diluted up to mark with HPLC grade methanol this 
gives a concentration of irbesartan 1000 µg/ml and amlodipine 
besylate 100 µg/ml. The above solution was filtered through 0.2 µ 
membrane filter. The 6 ml of the filtrate was transferred into a 100 
ml volumetric flask and diluted with mobile phase to get a 
concentration of 60 µg/ml and 6 µg/ml for irbesartan and 
amlodipine besylate respectively. 
Method validation 
The method was validated for accuracy, precision, linearity, 
specificity, robustness, limit of detection, limit of quantitation and 
system suitability. 
Linearity 
Linearity was performed by preparing standard solutions of 
irbesartan and amlodipine besylate at different concentration levels. 
Irbesartan was prepared in the concentration range of 10-70 µg/ml 
and 4-32 µg/ml for amlodipine besylate. Twenty microlitres of each 
concentration from both drug solutions were injected in duplicate 
into the HPLC system. The response was carried out at 238 nm and 
the corresponding chromatograms were recorded from these mean 
peak areas were calculated. The calibration curve was plotted by 
taking concentration on x-axis and peak areas on y-axis for both the 
drugs. 
Accuracy 
The accuracy of the method evaluated by standard addition method 
in which a known amount of standard drug was added to the fixed 
amount of pre-analyzed tablet solution. Percent recovery of 
irbesartan and amlodipine besylate was calculated at three 
concentration levels of 80 %, 100 % and 120 %. The solutions were 
analyzed in triplicate at each level. The percent recovery and % 
relative standard deviation (RSD) at each level was calculated. 
Precision 
Precision of the method was evaluated as system precision and 
method precision. 
To study the system precision, six replicate standard solutions of 
irbesartan and amlodipine besylate were analysed. The percent 
relative standard deviation (% RSD) was calculated for both 
irbesartan and amlodipine besylate. 
Method precision of the analytical method was carried out on six 
preparations from the tablet formulation and percentage amount of 
irbesartan and amlodipine besylate in the tablet formulation was 
calculated. The intraday and interday precision study were 
conducted for both irbesartan and amlodipine besylate. The mean % 
assay value, standard deviation and percent relative standard 
deviation was calculated [50]. 
Limit of detection (LOD) and limit of quantitatation (LOQ) 
LOD was measured by serially diluting the standard solutions of 
irbesartan and amlodipine besylate and determining the 
concentration was the response of sample peaks are three times the 
noise peak. LOQ was measured by serially diluting the standard 
solutions of irbesartan and amlodipine besylate and determining the 
concentration was the response of sample peaks are ten times the 
noise peak [51]. 
Robustness 
Robustness of the method was determined by making slight changes 
in the composition of organic phase±5%, pH
Specificity 
 by±0.2, flow rate by±0.1 
ml/min and detection wavelength by±2 nm. 
The specificity of the proposed method was determined against 
blank and placebo applications. Here mobile phase was used as 
blank and excipients like starch, lactose, magnesium stearate were 
used as placebo [52].  
Forced degradation studies 
Different stress conditions were used for the forced degradation 
studies of the formulation. These were also used to evaluate the 
specificity of the method. All the samples were diluted with mobile 
phase and filtered through 0.2 µ membrane filter.  
Acidic conditions 
Weighed accurately about twenty tablets and triturated it to a fine 
powder form. An a liquate of the powder equivalent to 100 mg of 
irbesartan and 10 mg of amlodipine besylate was transferred into a 
100 ml volumetric flask. To this added a 50 ml of diluent and 
sonicated for 10 min to dissolve the drug completely. Then 10 ml of 
5N HCl was added to it, refluxed for 6 hr at 60 °C, cooled to room 
temperature, neutralized with 5N NaOH and diluted up to the mark 
with the diluent. The above sample solution was filtered through 0.2 
µ nylon membrane filter. Pipetted 6 ml of the above filtered sample 
solution into a 100 ml volumetric flask and volume made up to the 
mark with diluent. 
Hemant et al. 




Weighed accurately about twenty tablets and triturated it to a fine 
powder form. An a liquate of the powder equivalent to 100 mg of 
irbesartan and 10 mg of amlodipine besylate was transferred into a 
100 ml volumetric flask. To this added a 50 ml of diluent and sonicated 
for 10 min to dissolve the drug completely. Then 10 ml of 5N NaOH 
was added to it, refluxed for 6 hr at 60 °C, cooled to room temperature, 
neutralized with 5N HCl and diluted up to the mark with the diluent. 
The above sample solution was filtered through 0.2 µ nylon membrane 
filter. Pipetted 6 ml of the above-filtered sample solution into a 100 ml 
volumetric flask and volume made up to the mark with diluent. 
Oxidative degradation 
Weighed accurately about twenty tablets and triturated it to a fine 
powder form. An a liquate of the powder equivalent to 100 mg of 
irbesartan and 10 mg of amlodipine besylate was transferred into a 
100 ml volumetric flask. To this added a 50 ml of diluent and sonicated 
for 10 min to dissolve the drug completely. Then 5 ml of 30 % 
hydrogen peroxide was added, refluxed for 2 hr at 60 °C, then cooled 
to room temperature and diluted up to the mark with diluents. The 
above sample solution was filtered through 0.2 µ nylon membrane 
filter. Pipetted 6 ml of the above-filtered sample solution into a 100 ml 
volumetric flask and volume made up to the mark with diluent. 
Thermal degradation 
Weighed accurately about twenty tablets and triturated it to a fine 
powder form. The powder sample was subjected to thermal stress at 
105 °C for about 2 d. An a liquate of the powder equivalent to 100 
mg of irbesartan and 10 mg of amlodipine besylate was transferred 
into a 100 ml volumetric flask. To this added a 50 ml of diluent and 
sonicated for 10 min to dissolve the drug completely the diluted up 
to mark with diluents. The above sample solution was filtered 
through 0.2 µ nylon membrane filter. Pipetted 6 ml of the above-
filtered sample solution into a 100 ml volumetric flask and volume 
made up to the mark with diluent. 
Photolytic degradation 
Weighed accurately about twenty tablets and triturated it to a fine 
powder form. The powder sample was subjected to UV light in a 
photo stability chamber for about 10 d. An a liquate of the powder 
equivalent to 100 mg of irbesartan and 10 mg of amlodipine besylate 
was transferred into a 100 ml volumetric flask. To this added a 50 ml 
of diluent and sonicated for 10 min to dissolve the drug completely 
the diluted up to mark with diluents. The above sample solution was 
filtered through 0.2 µ nylon membrane filter. Pipetted 6 ml of the 
above-filtered sample solution into a 100 ml volumetric flask and 
volume made up to the mark with diluent. 
RESULTS  
Optimization of chromatographic conditions 
In the present work, an analytical method based on RP-HPLC using 
UV detection was developed and validated for simultaneous 
estimation of irbesartan and amlodipine besylate in the 
pharmaceutical formulation. The selection of analytical conditions 
was based on the chemical nature of irbesartan and amlodipine 
besylate. A systematic study of various factors was undertaken by 
varying one parameter at a time and keeping all other conditions 
constant for development of an analytical method. Both irbesartan 
and amlodipine besylate were soluble in polar solvents, therefore, 
RP-HPLC was chosen. The selection of the stationary phase has been 
done on the basis of back pressure, resolution, peak shape, 
theoretical plates and day to day reproducibility in retention time 
resolution between irbesartan and amlodipine besylate peaks. After 
evaluating all these factors Enable C18 G column (250 x 4.6 mm i. d, 
5µ) was chosen for the analysis. The selection of buffer was based on 
the chemical structure of selected drug molecules. For optimization 
of mobile phase, preliminary trials were conducted under isocratic 
conditions using mobile phases composed of the mixture of solvents 
like water, methanol and actonitrile with or without different 
buffers in different combinations. A mixture of sodium acetate buffer 
pH
 
 4.0 and acetonitrile in the ratio of 30:70 v/v was found to be most 
suitable of all the combinations since the chromatographic peaks 
obtained were having good system suitability parameters. The Flow 
rate of the mobile phase was optimized based on the resolution 
between chromatographic peaks and minimal solvent consumption. 
The flow rate of mobile phase was changed from 0.5-2 ml/min. It 
was found from trials that 0.6 ml/min flow rate was ideal for 
successful elution of both drugs. For a selection of analytical 
wavelength standard solutions of both drugs were scanned in the 
wavelength range of 200-350 nm. A detection wavelength of 238 nm 
was selected. The chromatogram of the sample was shown in fig. 3. 
 
Fig. 3: Chromatogram of amlodipine besylate and Irbesartan 
 
Table 1: Linearity data for amlodipine besylate 
 S. No. Concentration of amlodipine besylate(µg/ml)  Peak area 
1 4 191223 
2 8 382459 
3 12 573701 
 4 16 764877 
5 20 956106 
6 24 1147398 
7 28 1338561 
8 32 1529772 
 Slope  47806 
 Intercept  11.786 
 Correlation Coefficient  0.9999 
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Linearity was studied by preparing standard solutions at different 
concentration levels. The linearity ranges for amlodipine besylate 
and irbesartan were found to be 4-32 µg/ml and 10-70 µg/ml 
respectively. The linear regression equation for amlodipine besylate 
was found to be 47806x+11.786 with correlation coefficient 0.9999. 
The linear regression equation for irbesartan was found to be 62825 
x-16.143 with correlation coefficient 0.9998. The calibration table 
for amlodipine besylate and irbesartan was shown in table 1 and 
table 2 respectively. The calibration curve of amlodipine besylate 
and irbesartan were shown in fig. 4 and fig. 5 respectively. 
Accuracy  
The percent recovery of irbesartan and amlodipine besylate was 
found to be 100.43-101 % and 100.07-100.52 %. This indicates the 
accuracy of the method. The results are shown in table 3 and 4. 
 
Table 2: Linearity data for Irbesartan 
 S. No. Concentration of Irbesartan(µg/ml)  Peak area 
 1 10 628247 
 2 20 1256484 
 3 30 1884758 
 4 40 2512971 
 5 50 3141220 
 6 60 3769498 
 7 70 4397771 
 Slope  62825 
 Intercept -16.143 
 Correlation Coefficient  0.9998 
 
 
Fig. 4: Linearity plot of amlodipine besylate 
 
 
Fig. 5: Linearity plot of irbesartan 
 
Table 3: Accuracy results of Irbesartan (n=3) 















n is number of determinations, SD is standard deviation 
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Table 4: Accuracy results of amlodipine besylate (n=3) 















n is number of determinations, SD is standard deviation 
 
Table 5: System precision results for irbesartan and amlodipine besylate 
Injection No. Peak area of irbesartan Peak area of amlodipine besylate 
1 3769498 286847 
2 3713456 289114 
3 3728862 279912 
4 3719841 285318 
5 3758423 284877 
6 3788912 286006 
Mean 3746499 285345.7 
SD 30277.22 3054.03 
%RSD 0.80 1.07 
 
Table 6: Method precision results for Irbesartan and amlodipine besylate (n=6) 
Set   Irbesartan  Amlodipine besylate 
Intraday (mean±SD) Interday (mean±SD) Intraday (mean±SD) Interday (mean±SD) 
% Assay 100.69±0.4385 101.04±0.3033 99.76±0.435 100.13±0.704 
% RSD 0.435 0.30 0.436 0.699 




The % relative standard deviation (RSD) for irbesartan was 
found to be 0.80 and for amlodipine besylate was found to be 
1.07 which are within the acceptance criteria of not more than 
2.0 indicates the precision of the method. The precision data was 
shown in table 5. 
Method precision 
The % relative standard deviation (RSD) for Intraday and Interday 
precision assay results of six preparations for irbesartan were found 
to be 0.435 and 0.30 respectively which are within the acceptance 
criteria of not more than 2.0 indicates the precision of the method. 
The % relative standard deviation (RSD) for Intraday and Interday 
precision assay results of six preparations for amlodipine besylate 
were found to be 0.436 and 0.699S respectively which are within the 
acceptance criteria of not more than 2.0 indicates the precision of 
the method. The precision data was shown in table 6. 
Limit of detection and limit of quantitation 
LOD and LOQ were calculated from the standard deviation of 
response and slope of the calibration curve of irbesartan and 
amlodipine besylate. The LOD and LOQ were found to be 0.0327 
μg/ml and 0.1097 μg/ml for amlodipine besylate and the LOD and 
LOQ for irbesartan were 0.0514 μg/ml and 0.1559 μg/ml, which 
shown that the developed method was sensitive and it can detect 
and quantify at the lower concentration.  
Robustness 
To evaluate the robustness of the developed method, small deliberate 
variations in optimized method parameters were made. The effect of the 
change in flow rate, change in pH, change in the composition of mobile 
phase and detection wavelength on retention time, tailing factor and 
theoretical plates were studied. The method was found to be unaffected 
by small changes in flow rate, change in pH, change in the composition of 
mobile phase and detection wavelength as shown in table 7 and table 8. 
Specificity 
Specificity is the ability to unequivocally assess the analyte in the 
presence of components that may be expected to be present. 
Typically, these might include impurities, degradants or matrix. 
Specificity of an analytical method is its ability to accurately and 
specifically measure the analyte of interest without interference 
from blank or placebo. The peak purities of amlodipine besylate and 
irbesartan were assessed by comparing the retention times of 
standard amlodipine besylate and irbesartan and the sample, and 
good correlation was obtained between the retention time of the 
standard and sample. Placebo and blank were injected and there 
were no peaks. There is no interference of degradation peaks on 
drug peaks hence, the method is specific. The specificity results are 
shown in table 9. 
 
Table 7: Robustness results for amlodipine besylate (n=3) 
Conditions % Assay (mean±SD)  System suitability parameters 
Theoretical plates (mean±SD) Tailing factor (mean±SD) 
Flow Rate 0.5 ml/min 99.23±0.33 5309±0.37 1.21±0.39 
Flow Rate 0.7 ml/min 99.14±0.21 5105±0.67 1.49±0.31 
Mobile Phase-Buffer(35):Acetonitrile(65) 100.83±0.78 4983±0.42 1.42±0.89 
Mobile Phase-Buffer(25):Acetonitrile(75) 99.12±0.96 4862±0.28 1.39±0.88 
Mobile Phase pH 101.32±0.66  3.8 4821±0.91 1.61±0.60 
Mobile Phase pH 99.55±0.54  4.2 5129±0.56 1.59±0.95 
Wavelength 236 nm 99.68±0.85 5157±0.44 1.53±0.87 
Wavelength 240 nm 99.87±0.21 5004±0.36 1.52±0.92 
 n is number of determinations, SD is the standard deviation 
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Table 8: Robustness results for Irbesartan (n=3) 
Conditions % Assay (mean±SD)  System suitability parameters 
Theoretical plates (mean±SD) Tailing factor(mean±SD) 
Flow Rate 0.5 ml/min  99.82±0.48 3340±0.67 1.33±0.87 
Flow Rate 0.7 ml/min 99.74±0.66 3030±0.39 1.54±0.91 
MobilePhase-Buffer(35):Acetonitrile(65) 100.25±0.75 3289±0.74 1.23±0.48 
Mobile Phase-Buffer(25):Acetonitrile (75) 100.63±0.58 3373±0.84 1.28±0.87 
Mobile Phase pH 99.66±0.67  3.8 3116±0.61 1.53±0.37 
Mobile Phase pH 100.79±0.91  4.2 3193±0.59 1.34±0.54 
Wavelength 236 nm  99.83±0.49 3288±0.78 1.37±0.82 
Wavelength 240 nm 99.78±0.78 3462±0.42 1.35±0.69 
 n is number of determinations, SD is standard deviation 
 
Table 9: Specificity results of the method (n=6) 
Name of solution Retention time (min) (mean±SD) 
Blank No peaks 
Placebo No Peaks 
Irbesartan 6.321±0.78 
Amlodipine Besylate 5.579±0.91 
 n is number of determinations, SD is standard deviation 
 
Table 10: Analysis of amlodipine besylate and Irbesartan in the commercial formulation 
Formulation Labelled claim(mg) Amount found*(mg) %Recovery*±%RSD 
Amlodipine besylate Irbesartan Amlodipine besylate Irbesartan Amlodipine besylate Irbesartan 
AMIX R TABLETS 10  100  9.96 100.06 99.96±0.42 100.6±0.56 
*Average of three determinations 
 
Analysis of commercial formulation 
The proposed method was applied for the determination of amlodipine 
besylate and irbesartan in marketed formulations available (AMIX R 
TABLETS). The % recovery was found to be 99.96±0.42 and 100.6±0.56 
for amlodipine besylate and irbesartan respectively table 10. 
Results of forced degradation studies 
Under acidic conditions amlodipine, besylate degraded to 3.44 % 
and irbesartan degraded to 10.66 %. In these stress conditions, the 
retention time of degradation peaks appears at 4.2132 min and 
5.182 min. In basic conditions amlodipine, besylate degraded to 
30.44 % and irbesartan degraded to 18.46%. Under these 
conditions, five degradant peaks appear at retention times of 3.812 
min, 4.252 min, 4.754 min, 5.255 min and 9.511 min. In oxidative 
conditions amlodipine, besylate degraded to 30.36 % and irbesartan 
to 30.42 %. Although both drugs degraded to a significant extent but 
only two minor peaks are detected at retention times of 3.345 min 
and 4.366 min. In thermal conditions amlodipine, besylate degraded 
to 0.43 % and irbesartan degraded to 5.06 % but there is no 
appearance of degradant peaks on the chromatogram. In photolytic 
conditions amlodipine, besylate degraded to 28.72 % and irbesartan 
degraded to 15.66 % here also both the drugs degraded to a 
significant extent but only two minor peaks are detected at retention 
times of 3.332 min and 4.414 min. Amlodipine besylate shown 
stability towards acidic and thermal in it degraded to a lesser extent 
whereas in basic, oxidative and photolytic it shown less stability in 
which it degraded to more extent. Irbesartan shown stability 
towards thermal conditions whereas in remaining conditions it 
degrades to more extent especially in Oxidative conditions. 
 
 
Fig. 6: Acid degradation chromatogram 
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Fig. 7: Base degradation chromatogram 
 
 
Fig. 8: Oxidative degradation chromatogram 
 
 
Fig. 9: Thermal degradation chromatogram 
 
 
Fig. 10: Photolytic degradation chromatogram 
Hemant et al. 
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Table 11: Forced degradation studies of Irbesartan and amlodipine besylate (n=3) 
Stress conditions Duration %Drug 
recovered 
(mean±SD) 
% Drug decomposed 
(mean±SD) 









Control Sample ---- 99.96±1.21 ---- 6.231±1.22 3440±1.89 1.43±0.56 
Acid Degradation 6 h 89.30±1.09 10.66±1.09 6.311±1.65 3598±1.73 1.52±0.89 
Alkaline degradation 6 h 81.5±0.98 18.46±0.98 6.396±1.89 3462±1.56 1.39±0.45 
Oxidative Degradation 2 h 69.54±1.65 30.42±1.65 6.210±0.36 3786±0.99 1.32±0.29 
Thermal Degradation 2 d 94.9±1.53 5.06±1.53 6.222±0.87 3580±1.09 1.31±0.84 
Photolytic Degradation 10 d 84.3±0.78 15.66±0.78 6.191±0.89 3582±1.54 1.56±0.99 
 Amlodipine Besylate 
Control Sample ---- 100.06±1.56 ----- 5.789±0.66 5225±0.92 1.24±0.74 
Acid Degradation 6 h 96.62±1.36 3.44±1.36 5.781±1.23 5853±0.39 1.19±0.52 
Alkaline Degradation 6 h 69.62±1.57 30.44±1.57 5.852±0.78 5674±0.66 1.26±0.33 
Oxidative Degradation 2 h 69.7±1.62 30.36±1.62 5.712±0.44 5281±0.98 1.21±0.92 
Thermal Degradation 2 d 99.63±1.78 0.43±1.78 5.712±0.60 5736±0.79 1.21±0.78 
Photolytic Degradation 10 d 71.34±1.41 28.72±1.41 5.743±0.61 5452±1.67 1.32±0.68 
 n is number of determinations, SD is standard deviation 
 
DISCUSSION 
The present RP-HPLC method is a simple, precise, specific, accurate, 
linear and robust for analyzing irbesartan and amlodipine besylate 
in the sample mixture. The results obtained from the above set of 
observations prove that the method is useful in qualitative and 
quantitative analysis of irbesartan and amlodipine besylate in 
dosage forms. There are some RP-HPLC methods reported for the 
estimation of irbesartan and amlodipine besylate in dosage forms 
and biological fluids but the methods have the drawbacks as not of 
stability indicating [46, 47], having long retention time and low 
linearity range [48]. In the present method, a mixture of sodium 
acetate buffer pH
CONCLUSION 
 4.0 and acetonitrile in the ratio of 30:70 v/v as 
mobile phase found to be most suitable of analysis of irbesartan and 
amlodipine besylate, since the chromatographic peaks obtained 
were having good system suitability parameters. The method was 
validated according to ICH guidelines and results were in 
compliance of ICH guidelines. The linearity of the method had a good 
correlation with concentration and peak area. The correlation 
coefficient of irbesartan and amlodipine besylate was found to be 
0.999, which indicates good linear relationship over concentration 
range 10-70 μg/ml and 8-32 μg/ml for irbesartan and amlodipine 
besylate respectively. The % RSD values in intra-day and inter-day 
precision study were found to be less than 2 for irbesartan and 
amlodipine besylate, which indicate the method was precise. The 
amount of drug recovery was 99.96 % for amlodipine besylate and 
100.6 % for irbesartan. Hence, the present developed method was 
said to be suitable for the analysis of drugs in their pharmaceutical 
dosage form. The developed method is stability indicating in nature, 
use of economical mobile phase and short chromatographic time. 
The proposed method for the simultaneous estimation of amlodipine 
besylate and irbesartan validated as per the international conference on 
organization (ICH) guidelines and it is simple, specific and reliable. The 
data generated from the forced degradation studies enabled the 
evaluation of amlodipine besylate and irbesartan stability under a 
variety of ICH recommended conditions. These data are valuable for the 
safety and potency assessment of a drug product. Furthermore, this 
simple and rapid RP-HPLC method can also be used successfully for the 
determination of amlodipine besylate and irbesartan in pharmaceutical 
formulations without any interference from the excipient. 
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